gms | German Medical Science

23rd Annual Meeting of the German Retina Society

German Retina Society

24.09. - 25.09.2010, Freiburg

Expression and localisation of VEGFA165b in eyes with retinal vein occlusion

Meeting Abstract

  • Christoph Ehlken - University Eye Clinic Freiburg i. Br.
  • E.S. Rennel - University Eye Clinic Freiburg i. Br.
  • D. Michels - University Eye Clinic Freiburg i. Br.
  • B. Grundel - University Eye Clinic Freiburg i. Br.
  • A. Pielen - University Eye Clinic Freiburg i. Br.
  • B. Junker - University Eye Clinic Freiburg i. Br.
  • A. Stahl - University Eye Clinic Freiburg i. Br.
  • L.L. Hansen - University Eye Clinic Freiburg i. Br.
  • N. Feltgen - University Eye Clinic Freiburg i. Br.
  • H. Agostini - University Eye Clinic Freiburg i. Br.
  • G. Martin - University Eye Clinic Freiburg i. Br.

German Retina Society. 23rd Annual Conference of the German Retina Society. Freiburg i. Br., 24.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10rg72

DOI: 10.3205/10rg72, URN: urn:nbn:de:0183-10rg726

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2010/10rg72.shtml

Published: September 21, 2010

© 2010 Ehlken et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: In contrast to its splice variant VEGFA165, VEGFA165b acts as an anti-proliferative agent. The balance of VEGFA165b to VEGFA165 is shifted towards a proangiogenic state in angioproliferative diseases, such as proliferative diabetic retinopathy. The aim of our study was to examine the expression and localisation of VEGFA165b in the eye with a special focus on retinal vein occlusion.

Methods: Vitreous samples of patients with branch or central retinal vein occlusion (BRVO, resp. CRVO) were examined for the expression of VEGFA165b by means of ELISA and were compared to samples of patients with macular pucker as controls. The localisation of VEGFA165b in the eye was determined by immunohistological staining in eyes with different diseases, such as retinal vein occlusion or tumors.

Results: The balance of VEGFA165b to VEGFA165 was shifted towards VEGFA165 in patients with RVO. The effect was more pronounced in CRVO than in BRVO. In immunohistological stainings, VEGFA165b could be detected in the tunica media of arteries and retinal arterioles, as well as in inflamed areas and neural or glial cells.

Conclusions: The balance of VEGFA165b to VEGFA165 is shifted towards a proangiogenic state in vitreous samples of patients with RVO. The localisation of VEGFA165b resembles that of VEGFA165. Influencing the balance of VEGFA165b to VEGFA165 might be a feasible approach in patients with angioproliferative disease.